Genmab — December 2023
-
the abstracts of the posters are all you will get i think, need to be lucky to find someone posting a picture on twitter...
https://ash.confex.com/ash/2023/webprogram/start.html#srch=words|epcoritamab|method|and|pge|1|byDayany|any|bySessionTypeP|1|bySymposiumany|any|byAudienceany|any -
Gen burde nok stoppe med at deltage i den slags konferencer - same story every time

-
The Danish company Hemab has today announced that FDA has granted fast track to their phase 1/2 –study of HMB-001. This is a novel bispecific antibody designed to be the first prophylactic treatment for Glanzmann Thrombasthenia (GT). I believe this is based on technology from Genmab as mentioned by MedWatch 21/2 2023. Can anyone confirm and does anyone know how Genmab may be paid (Licence fee or royalty ??)
-
i have this link https://patents.google.com/patent/WO2020212415A1/en with a comment "so probably a DuoBody
" can't remember why i thought that so
i guess i'll have to read through it again
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind